maripoc-banner-picture-with-kids-smiling
Home | News | Mr. Vesa Kemppainen appointed as the new CEO
28.3.2024

Press Release: New Innovation Makes Coronavirus Rapid Testing More Accurate than Laboratory Tests

25.10.2022

Press release: New scientific reports demonstrate the high accuracy of mariPOC COVID-19 tests in decentralized testing

21.6.2022

Nasal sampling and EU RAT list

20.7.2021

mariPOC COVID-19 tests are suitable for travel certificates in the EU

4.3.2021

Press release: ArcDia launches a quick and automated COVID-19 antigen test with superior performance

10.9.2020

Press release: Bruker to distribute ArcDia’s mariPOC® products for automated antigen POCT of COVID-19 and other infectious diseases in Central Europe

25.5.2020

Press release: ArcDia Ltd’s automated coronavirus point-of-care test CE marked and available

27.4.2020

Press Release: ArcDia Ltd reports a breakthrough in the development of an automated coronavirus point-of-care test

26.3.2020

Press Release: ArcDia’s products would allow testing of all respiratory tract and COVID-19 patients in Finland

11.3.2020

Press Release: ArcDia International Ltd develops a COVID-19 test for primary care

14.10.2019

Pathogen Detection in Perianal Streptococcal Dermatitis

7.10.2019

Mr. Vesa Kemppainen appointed as the new CEO

30.9.2019

New mariPOC® publication: Evaluation of a Gastrointestinal Pathogen Panel Immunoassay in Stool Testing of Patients with Suspected Clostridioides (Clostridium) difficile Infection.

30.9.2019

New mariPOC® publication: Comparison of phenotypic and genotypic diagnosis of acute human bocavirus 1 infection in children.

9.4.2019

ArcDia has entered into an exclusive license agreement with Xinhua Healthcare for the commercialisation of ArcDia’s mariPOC® technology in China

24.5.2018

mariPOC® ensures lower probability for C. difficile misdiagnosis with precision

8.2.2018

New research data shows that influenza antigen testing correlates best with the infectivity period

1.11.2017

Press release: New test for detection of C. difficile infection

2.8.2017

New QuickStrepA

6.4.2017

Study: Diagnosis of respiratory tract infections caused by human bocavirus 1

7.3.2017

New mariPOC influenza A virus test with significantly improved sensitivity

21.12.2016

New test for Flu A

8.6.2016

World’s fastest antibiotic resistance testing

28.4.2016

New mariPOC® Gastro test available

17.3.2016

Detection and monitoring of human bocavirus 1 infection by a new rapid antigen test

2.2.2016

ArcDia contributes solving the global problem of antimicrobial resistance

9.12.2015

Press release: Spanish clinical study demonstrates mariPOC’s excellent performance

1.9.2015

ArcDia is developing pandemics preparedness

11.5.2015

The diagnostics of group A streptococcus from pharyngeal swab samples by bacterial culture is challenged by a novel mariPOC point of care test.

31.10.2014

The Flu Season Has Begun – mariPOC® Helps

9.10.2014

Nobel Prize awarded to mariPOC® sister technology

3.10.2014

The Evolution of Rapid POC Tests for Infectious Disease Diagnostics: An Exclusive SelectScience Interview

9.4.2014

ArcDia Receives Frost & Sullivan Award for Point-of-Care Product Leadership!

24.1.2014

ArcDia launches world’s first antigen test for human bocavirus – Press Release

24.9.2013

New press release

7.10.2019

Mr. Vesa Kemppainen appointed as the new CEO

Mr. Vesa Kemppainen has been appointed as the CEO of ArcDia International Ltd as of October 7th 2019.

Dr. Aleksi Soini, co-founder of ArcDia, will continue to contribute to ArcDia as Senior Vice President of Business Development.